Synthesis of 4(5)-[5-(Aminomethyl)tetrahydrofuran-2-yl- or 5- (aminomethyl)-2,5-dihydrofuran-2-yl]imidazoles by efficient use of a PhSe group: Application to novel histamine H3-ligands

Journal of Organic Chemistry

Volumn 64, Issue 23, 1999, Pages 8608-8615

  Harusawa, Shinya ^a   Imazu, Tomonari ^a   Takashima, Seiichiroh ^a   Araki, Lisa ^a   Ohishi, Hirofumi ^a   Kurihara, Takushi ^a   Sakamoto, Yasuhiko ^b   Yamamoto, Yumiko ^c   Yamatodani, Atsushi ^c  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Azwell Inc   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[5 (AMINOMETHYL) 2,5 DIHYDROFURAN 2 YL]IMIDAZOLE; [5 (AMINOMETHYL)TETRAHYDROFURAN 2 YL]IMIDAZOLE; BENZENE DERIVATIVE; HISTAMINE H3 RECEPTOR; LIGAND; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CYCLIZATION; HYDROGEN BOND; OXIDATION; STEREOISOMERISM; SYNTHESIS;

EID: 0033550240     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo9910637     Document Type: Article

References (46)

1. Preliminary communication: Harusawa, S.; Imazu, T.; Takashima, S.; Araki, L.; Ohishi, H.; Kurihara, T.; Yamamoto, Y.; Yamatodani, A. Tetrahedron Lett. 1999, 40, 2561.
2. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Nature (London) 1983, 302, 837.
3. Arrang, J.-M.; Garbag, M.; Lancelot, J.-C.; Lecomte, J.-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J.-C. Nature (London) 1987, 357, 117.
4. 3 receptor, see: (a) Schunak, W. Actual. Chim. Ther. 1993, 20, 9. (b) Schunack, W.; Stark, H. Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 173. (c) Leurs, R.; Vollinga, R. C.; Timmerman, H. Prog. Drug Res. 1995, 45, 107. (d) Schlicker, E.; Malinowska, B.; Kathmann, M.; Göthert, M. Fundam Clin Pharmacol. 1994, 8, 128. (e) Stark, H.; Schlicker, E.; Schunack, W. Drugs Future 1998, 21, 507. (f) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. TiPS 1998, 19, 177.
5. 3 receptor, see: (a) Schunak, W. Actual. Chim. Ther. 1993, 20, 9. (b) Schunack, W.; Stark, H. Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 173. (c) Leurs, R.; Vollinga, R. C.; Timmerman, H. Prog. Drug Res. 1995, 45, 107. (d) Schlicker, E.; Malinowska, B.; Kathmann, M.; Göthert, M. Fundam Clin Pharmacol. 1994, 8, 128. (e) Stark, H.; Schlicker, E.; Schunack, W. Drugs Future 1998, 21, 507. (f) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. TiPS 1998, 19, 177.
6. 3 receptor, see: (a) Schunak, W. Actual. Chim. Ther. 1993, 20, 9. (b) Schunack, W.; Stark, H. Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 173. (c) Leurs, R.; Vollinga, R. C.; Timmerman, H. Prog. Drug Res. 1995, 45, 107. (d) Schlicker, E.; Malinowska, B.; Kathmann, M.; Göthert, M. Fundam Clin Pharmacol. 1994, 8, 128. (e) Stark, H.; Schlicker, E.; Schunack, W. Drugs Future 1998, 21, 507. (f) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. TiPS 1998, 19, 177.
7. 3 receptor, see: (a) Schunak, W. Actual. Chim. Ther. 1993, 20, 9. (b) Schunack, W.; Stark, H. Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 173. (c) Leurs, R.; Vollinga, R. C.; Timmerman, H. Prog. Drug Res. 1995, 45, 107. (d) Schlicker, E.; Malinowska, B.; Kathmann, M.; Göthert, M. Fundam Clin Pharmacol. 1994, 8, 128. (e) Stark, H.; Schlicker, E.; Schunack, W. Drugs Future 1998, 21, 507. (f) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. TiPS 1998, 19, 177.
8. 3 receptor, see: (a) Schunak, W. Actual. Chim. Ther. 1993, 20, 9. (b) Schunack, W.; Stark, H. Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 173. (c) Leurs, R.; Vollinga, R. C.; Timmerman, H. Prog. Drug Res. 1995, 45, 107. (d) Schlicker, E.; Malinowska, B.; Kathmann, M.; Göthert, M. Fundam Clin Pharmacol. 1994, 8, 128. (e) Stark, H.; Schlicker, E.; Schunack, W. Drugs Future 1998, 21, 507. (f) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. TiPS 1998, 19, 177.
9. 3 receptor, see: (a) Schunak, W. Actual. Chim. Ther. 1993, 20, 9. (b) Schunack, W.; Stark, H. Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 173. (c) Leurs, R.; Vollinga, R. C.; Timmerman, H. Prog. Drug Res. 1995, 45, 107. (d) Schlicker, E.; Malinowska, B.; Kathmann, M.; Göthert, M. Fundam Clin Pharmacol. 1994, 8, 128. (e) Stark, H.; Schlicker, E.; Schunack, W. Drugs Future 1998, 21, 507. (f) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. TiPS 1998, 19, 177.
10. Wada, H.; Inagaki, N.; Yamatodani, A.; Watanabe, T. Trends Neurosci. 1991, 14, 415.
11. Schwartz, J. C.; Arrang, J. M.; Garbarg, M.; Pollard, H.; Ruat, M. Physiol Rev. 1991, 71, 1.
12. Yamatodani, A.; Inagaki, N.; Panula, P.; Itowi, N.; Watanabe, T.; Wada, H. In Handbook of Experimental Pharmacology. Histamine and Histamine antagonists; Uvnäs, B., Ed.; Springer-Verlag: Berlin and Heidelberg, 1991; Vol. 97, pp 243-283.
13. Onodera, K.; Yamatodani, A.; Watanabe, T.; Wada, H. Prog Neurobiol. 1994, 42, 685.
14. Ichinose, M.; Stretton, C. D.; Schwartz, J.-C.; Barnes P. J. Br. J. Pharmacol. 1989, 97, 13.
15. Hey, J. A.; del Prado, M.; Egan, R. W.; Kreutner, W.; Chapman, R. Eur. J. Phamacol. 1992, 211, 421.
16. Shin, N.-Y.; Lupo, A. T., Jr.; Aslanian, R.; Orlando, S.; Piwinski, J. J.; Green, M. J.; Ganguly, A. K.; Clark, M. A.; Tozzi, S.; Kreutner, W.; Hey, J. A. J. Med. Chem. 1995, 38, 1593.
17. Nagy, P. I.; Durant, G. J.; Hoss, W. P.; Smith, D. A. J. Am. Chem. Soc. 1994, 116, 4898.
18. Mazurek, A. P.; Karpinska, G. Z. Naturforsch. 1994, 49c, 471.
19. Kovalainen, J. T.; Christiaans, J. A. M.; Poso, A.; Vepsäläinen, J.; Laatikainen, R.; Gynther, J. Tetrahedron Lett. 1999, 40, 2425.
20. Arrang, J. M.; Garbarg, M.; Schunack, W.; Schwartz, J. C. Eur. Patent Appl. 0214058, 1987.
21. Khan, M. A.; Yates, S. L.; Tedford, C. E.; Kirschbaum, K.; Philips, J. Bioorg. Med. Chem. Lett. 1997, 7, 3017.
22. De Esch, I. J. P.; Vollinga, R. C.; Goubitz, K.; Schenk, H.; Appelberg, U.; Hacksell, U.; Lemstra, S.; Zuiderveld, O. P.; Hoffmann, M.; Leurs, R.; Menge, W. M. P. B.; Timmerman, H. J. Med. Chem. 1999, 42, 1115.
23. Khan et al. synthesized only trans-cyclopropylhistamine via diastereoselective cyclopropanation, and the synthetic attempts for cis-cyclopropylhistamine by Timmerman et al. were unsuccessful.
24. (a) Harusawa, S.; Murai, Y.; Moriyama, H.; Ohishi, H.; Yoneda, R.; Kurihara, T. Tetrahedron Lett. 1995, 36, 3165.
25. (b) Harusawa, S.; Murai, Y.; Moriyama, H.; Imazu, T.; Ohishi, H.; Yoneda, R.; Kurihara, T. J. Org. Chem. 1996, 61, 4405.
26. Harusawa, S.; Moriyama, H.; Murai, Y.; Imazu, T.; Ohishi, H.; Yoneda, R.; Kurihara, T.; Hata, H.; Sakamoto, Y. Chem. Pharm. Bull. 1997, 45, 53.
27. Lipp, R.; Arrang, J. M.; Garbarg, M.; Luger, P.; Schwartz, J. C.; Schunack, W. J. Med. Chem. 1992, 35, 4434.
28. Arrang, J. M.; Schwartz, J. C.; Schunack, W. Eur. J. Pharmacol. 1985, 117, 109.
29. Mochizuki, T.; Yamatodani, A.; Okakura, K.; Takemura, M.; Inagaki, N.; Wada, H. Naunyn Schmiedebergs Arch. Pharmacol. 1991, 343, 190.
30. Yamamoto, Y.; Mochizuki, T.; Okakura-Mochizuki, K.; Uno, A.; Yamatodani, A. Methods Find. Exp. Clin. Pharmacol. 1997, 19, 289.
31. Taniguchi, M.; Koga, K.; Yamada, S. Tetrahedron 1974, 30, 3547.
32. Beach, J. W.; Kim, H. O.; Jeong, L. S.; Nampalli, S.; Islam, Q.; Ahn, S. K.; Babu, J. R.; Chu, C. K. J. Org. Chem. 1992, 57, 3887.
33. Baldwin, J. E. J. Chem. Soc., Chem. Commun. 1976, 734.
34. Andrey, O.; Ducry, L.; Landais, Y. Planchenault, D.; Weber, V. Tetrahedron 1997, 53, 4339 and references therein.
35. For recent reviews on the chemistry, biochemistry, and synthesis of C-nucleoside analogues, see: (a) Watanabe, K. A. The Chemistry of C-Nucleosides. In Chemistry of Nucleosides and Nucleotides; Townsend, L. B., Ed.; Plenum Press: New York, 1994; Vol. 3, pp 421-535. (b) Shaban, M. A. E.; Nasr, A. Z. The Chemistry of C-Nucleosides and Their Analogues I: C-Nucleosides of Hetero Monocyclic Bases. In Advances In Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic Press: New York, 1997; Vol. 68, pp 223-432. (c) Levy, D. E.; Tang, C. The Chemistry of C-Glycosides. In Tetrahedron Organic Chimistry Series; Baldwin, J. E., Magnus, P. D., Eds.; Pergamon: New York, 1995.
36. For recent reviews on the chemistry, biochemistry, and synthesis of C-nucleoside analogues, see: (a) Watanabe, K. A. The Chemistry of C-Nucleosides. In Chemistry of Nucleosides and Nucleotides; Townsend, L. B., Ed.; Plenum Press: New York, 1994; Vol. 3, pp 421-535. (b) Shaban, M. A. E.; Nasr, A. Z. The Chemistry of C-Nucleosides and Their Analogues I: C-Nucleosides of Hetero Monocyclic Bases. In Advances In Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic Press: New York, 1997; Vol. 68, pp 223-432. (c) Levy, D. E.; Tang, C. The Chemistry of C-Glycosides. In Tetrahedron Organic Chimistry Series; Baldwin, J. E., Magnus, P. D., Eds.; Pergamon: New York, 1995.
37. For recent reviews on the chemistry, biochemistry, and synthesis of C-nucleoside analogues, see: (a) Watanabe, K. A. The Chemistry of C-Nucleosides. In Chemistry of Nucleosides and Nucleotides; Townsend, L. B., Ed.; Plenum Press: New York, 1994; Vol. 3, pp 421-535. (b) Shaban, M. A. E.; Nasr, A. Z. The Chemistry of C-Nucleosides and Their Analogues I: C-Nucleosides of Hetero Monocyclic Bases. In Advances In Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic Press: New York, 1997; Vol. 68, pp 223-432. (c) Levy, D. E.; Tang, C. The Chemistry of C-Glycosides. In Tetrahedron Organic Chimistry Series; Baldwin, J. E., Magnus, P. D., Eds.; Pergamon: New York, 1995.
38. Okabe, M.; Sun, R. C.; Tam, S. Y. K.; Todaro, L. J.; Coffen, D. L. J. Org. Chem. 1988, 53, 4780.
39. Jung, M. E., Lyster, M. A. J. Org. Chem. 1977, 42, 3761.
40. Williams, D. R.; Brown, D. L.; Benbow, J. W. J. Am. Chem. Soc. 1989, 111, 1923.
41. The isolated yield was variable and less satisfactory owing to the difficulty in product isolation from contamination with some inorganic material.
42. Scott, N. D.; Walker, J. F.; Hansley, V. L. J. Am. Chem. Soc. 1936, 58, 2442.
43. Deprotection by hydrazine hydrate caused a partial hydrogenation of the double bond in 3.
44. Harusawa, S.; Kawabata, M.; Murai, Y.; Yoneda, R.; Kurihara, T. Chem. Pharm. Bull. 1995, 43, 152.
45. Rosemryer, H.; Seela, F. Helv. Chim. Acta 1988, 71, 1573.
46. Kaskar, B.; Heise, G. L.; Michalak, R. S.; Vishnuvajjala, B. R. Synthesis 1990, 1031.